X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
ATH-1017 (fosgonimeton) is a potentially first-in-class, investigational, small molecule designed to positively modulate the hepatocyte growth factor (HGF) system. It is under phase 2/3 clinical development for the treatment of mild-to-moderate Alzheimer’s Disease.
Lead Product(s): Fosgonimeton
Therapeutic Area: Neurology Product Name: ATH-1017
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 03, 2024
Details:
ATH-1017 (fosgonimeton) is a HGF modulator, small molecule drug candidate, which is being evaluated for the treatment of Parkinson’s disease dementia.
Lead Product(s): Fosgonimeton
Therapeutic Area: Neurology Product Name: ATH-1017
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2023
Details:
Fosgonimeton is a small molecule designed to enhance the activity of hepatocyte growth factor (HGF) and its receptor, MET, an endogenous repair mechanism for a healthy nervous system.
Lead Product(s): Fosgonimeton
Therapeutic Area: Neurology Product Name: ATH-1017
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2022
Details:
ATH-1017 (fosgonimeton) is a small molecule designed to enhance the activity of hepatocyte growth factor (HGF) and its receptor, MET, to impact neurodegeneration and regenerate brain tissue.
Lead Product(s): Fosgonimeton
Therapeutic Area: Neurology Product Name: ATH-1017
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 21, 2022
Details:
ATH-1017 (fosgonimeton) is a small molecule designed to enhance the activity of hepatocyte growth factor (HGF) and its receptor, MET, to impact neurodegeneration and regenerate brain tissue.
Lead Product(s): Fosgonimeton
Therapeutic Area: Neurology Product Name: ATH-1017
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2022
Details:
ATH-1017 (fosgonimeton) is a small molecule designed to enhance the activity of hepatocyte growth factor (HGF) and its receptor, MET, to impact neurodegeneration and regenerate brain tissue.
Lead Product(s): Fosgonimeton
Therapeutic Area: Neurology Product Name: ATH-1017
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2022
Details:
Plasma biomarker data in pre-specified subgroup analysis showed statistically significant reduction in NfL, in subjects treated with fosgonimeton monotherapy compared to placebo, and showed a numerical reduction in NfL across all fosgonimeton treated patients
Lead Product(s): Fosgonimeton
Therapeutic Area: Neurology Product Name: ATH-1017
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2022
Details:
Fosgo-AM, the active metabolite of Fosgonimeton (ATH-1017), a novel, small molecule positive modulator of the HGF/MET system is neuroprotective in primary neuron culture demonstrates neuroprotective effects in primary neuron cultures.
Lead Product(s): Fosgonimeton
Therapeutic Area: Neurology Product Name: ATH-1017
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 02, 2022
Details:
Fosgonimeton (ATH-1017) is a small molecule designed to enhance the activity of hepatocyte growth factor (HGF) and its receptor, MET, to impact neurodegeneration and regenerate brain tissue.
Lead Product(s): Fosgonimeton
Therapeutic Area: Neurology Product Name: ATH-1017
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 25, 2022
Details:
Primary endpoint of change in biomarker ERP P300 latency was not statistically significant for the full study population as combination of ATH-1017 (fosgonimeton) and standard-of-care (AChEIs) given together showed potential diminished effect of fosgonimeton.
Lead Product(s): Fosgonimeton
Therapeutic Area: Neurology Product Name: ATH-1017
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2022
Details:
ATH-1017 (fosgonimeton) is a small molecule designed to enhance the activity of hepatocyte growth factor (HGF) and its receptor, MET, to impact neurodegeneration and regenerate brain tissue.
Lead Product(s): Fosgonimeton
Therapeutic Area: Neurology Product Name: ATH-1017
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 09, 2022
Details:
Baseline data demonstrate that patient population enrolled in ACT-AD study is representative of Alzheimer’s population and appropriate to evaluate effectiveness of ATH-1017 (fosgonimeton) on ERP P300 latency, a functional, objective measure of working memory processing speed.
Lead Product(s): Fosgonimeton
Therapeutic Area: Neurology Product Name: ATH-1017
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 20, 2022
Details:
ATH-1017 (fosgonimeton), a small molecule designed to enhance the activity of hepatocyte growth factor (HGF) and its receptor, MET, to impact neurodegeneration and regenerate brain tissue.
Lead Product(s): Fosgonimeton
Therapeutic Area: Neurology Product Name: ATH-1017
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2022
Details:
ATH-1017 is an investigational drug designed to support the growth and survival of nerve cells. ThE study, will determine the safety and effectiveness of ATH-1017 to improve cognition in people with mild to moderate Alzheimer's disease.
Lead Product(s): Fosgonimeton
Therapeutic Area: Neurology Product Name: ATH-1017
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 02, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
